Literature DB >> 9099703

Identification and expression of the cDNA-encoding human mesotrypsin(ogen), an isoform of trypsin with inhibitor resistance.

C N Nyaruhucha1, M Kito, S I Fukuoka.   

Abstract

The cDNA encoding a novel isoform of human trypsinogen was identified. The isoelectric points of the proenzyme and active forms calculated from the deduced amino acid sequence are consistent with those of mesotrypsin(ogen), known to be an inhibitor-resistant trypsin isoform. The cDNA attached with a bacterial signal peptide sequence was expressed in Escherichia coli. The recombinant proenzyme purified from periplasm showed enterokinase-dependent activation similar to a major isoform of human trypsinogen. The enzyme was far less inhibited by trypsin inhibitors such as soybean trypsin inhibitor, aprotinin, or pancreatic secretory trypsin inhibitor than the control trypsin. A gel filtration assay showed that the enzyme and aprotinin did not form a stable complex. It is noteworthy that the amino acid at position 198, which is in close vicinity to the active Ser, is Arg while those of other major trypsins are all Gly. It is concluded that the cloned cDNA encodes human mesotrypsinogen, a unique isoform of trypsinogen with inhibitor resistance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9099703     DOI: 10.1074/jbc.272.16.10573

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Hereditary pancreatitis: new insights into acute and chronic pancreatitis.

Authors:  D C Whitcomb
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

2.  A single mutation in the activation site of bovine trypsinogen enhances its accumulation in the fermentation broth of the yeast Pichia pastoris.

Authors:  José Hanquier; Yannick Sorlet; Dominique Desplancq; Laurence Baroche; Marc Ebtinger; Jean-François Lefèvre; Franc Pattus; Charles L Hershberger; Alain A Vertès
Journal:  Appl Environ Microbiol       Date:  2003-02       Impact factor: 4.792

3.  Human mesotrypsin exhibits restricted S1' subsite specificity with a strong preference for small polar side chains.

Authors:  Edit Szepessy; Miklós Sahin-Tóth
Journal:  FEBS J       Date:  2006-06-05       Impact factor: 5.542

Review 4.  Human pancreatic digestive enzymes.

Authors:  David C Whitcomb; Mark E Lowe
Journal:  Dig Dis Sci       Date:  2007-01-05       Impact factor: 3.199

Review 5.  Biochemical and structural insights into mesotrypsin: an unusual human trypsin.

Authors:  Moh'd A Salameh; Evette S Radisky
Journal:  Int J Biochem Mol Biol       Date:  2013-09-13

6.  Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.

Authors:  Alexandre P Alloy; Olumide Kayode; Ruiying Wang; Alexandra Hockla; Alexei S Soares; Evette S Radisky
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

7.  The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity.

Authors:  Moh'd A Salameh; Alexei S Soares; Alexandra Hockla; Derek C Radisky; Evette S Radisky
Journal:  Biochem J       Date:  2011-11-15       Impact factor: 3.857

8.  Proteolytic activation of the human epithelial sodium channel by trypsin IV and trypsin I involves distinct cleavage sites.

Authors:  Silke Haerteis; Annabel Krappitz; Matteus Krappitz; Jane E Murphy; Marko Bertog; Bettina Krueger; Regina Nacken; Hyunjae Chung; Morley D Hollenberg; Wolfgang Knecht; Nigel W Bunnett; Christoph Korbmacher
Journal:  J Biol Chem       Date:  2014-05-19       Impact factor: 5.157

9.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

10.  Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors.

Authors:  Richárd Szmola; Zoltán Kukor; Miklos Sahin-Tóth
Journal:  J Biol Chem       Date:  2003-09-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.